[go: up one dir, main page]

WO2001060401A1 - Methodes de modulation de l'activation du recepteur 4 active par des proteases (par4) avec de la cathepsine g - Google Patents

Methodes de modulation de l'activation du recepteur 4 active par des proteases (par4) avec de la cathepsine g Download PDF

Info

Publication number
WO2001060401A1
WO2001060401A1 PCT/US2001/004987 US0104987W WO0160401A1 WO 2001060401 A1 WO2001060401 A1 WO 2001060401A1 US 0104987 W US0104987 W US 0104987W WO 0160401 A1 WO0160401 A1 WO 0160401A1
Authority
WO
WIPO (PCT)
Prior art keywords
par4
cathepsin
activation
agent
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/004987
Other languages
English (en)
Inventor
Gilberto Sambrano
Shaun R. Coughlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Priority to AU2001238366A priority Critical patent/AU2001238366A1/en
Publication of WO2001060401A1 publication Critical patent/WO2001060401A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Definitions

  • This invention relates to the field of platelet activation via protease activated receptors (PAR). More specifically, this invention relates to cathepsin G-mediated protease activated receptor 4 (PAR4) activation, and methods for modulating cathepsin G-mediated PAR4 activation and/or platelet activation and methods for screening agents that modulate cathepsin G-mediated PAR4 activation and/or platelet activation.
  • PAR protease activated receptors
  • Platelet activation is critical for normal hemostasis and plays key roles in dealing with tissue remodeling, injury and inflammatory stimuli. Platelet-dependent arterial thrombosis underlies most myocardial infarctions. Insufficient activation of platelets causes disorders such as hemophilia. Thrombin is the most potent activator of platelets.
  • thromboin a coagulation protease generated at sites of vascular injury, activates platelets, leukocytes, and mesenchymal cells. Vu et al. (1991a) Cell 64:1057-1068. Activation of platelets by thrombin is thought to be critical for hemostasis and thrombosis.
  • thrombin inhibitors block platelet-dependent thrombosis, which is the cause of most heart attacks and strokes in humans.
  • Available data in humans suggest that thrombosis in arteries can be blocked by inhibitors of platelet function and by thrombin inhibitors.
  • thrombin's actions on platelets contribute to the formation of clots that cause heart attack and stroke.
  • thromboin's other actions on vascular endothelial cells and smooth muscle cells, leukocytes, and fibroblasts may mediate inflammatory and proliferative responses to injury, as occur in normal wound healing and a variety of diseases (atherosclerosis, resternosis, pulmonary inflammation (ARDS), glomerulosclerosis, etc.).
  • Receptors are cell-associated proteins that bind to a bioactive molecule (i.e., a ligand) and mediate the effect of the ligand on the cell.
  • Membrane-bound receptors are characterized by a multi-domain structure (also sometimes referred to as a "multi-peptide", wherein subunit binding and signal transduction can be functions of separate subunits) comprising an extracellular ligand-binding domain and an intracellular effector domain that is typically involved in signal transduction. Binding of ligand to receptor results in a conformational change in the receptor that causes an interaction between the effector domain and other molecule(s) in the cell. This interaction in turn leads to an alteration in the metabolism of the cell.
  • Metabolic events that are linked to receptor-ligand interactions include gene transcription, phosphorylation, dephosphorylation, increases in cyclic AMP production, mobilization of cellular calcium, mobilization of membrane lipids, cell adhesion, hydrolysis of inositol lipids and hydrolysis of phospholipids.
  • Thrombin signaling is mediated at least in part by a family of G-protein-coupled protease-activated receptors (PARs), for which PARl is the prototype.
  • PARs G-protein-coupled protease-activated receptors
  • PARl, PAR3, and PAR4 can be activated by thrombin. Nu et al. (1991a); Kahn et al. (1998) Nature 394:690-694; Ishihara et al. (1997) Nature 386:502-506; Xu et al. (1998) Proc. Natl Acad. Sci. USA 95:6642-6646; Dery and Bunnett (1999) Biochem. Soc. Trans. 27:246-254. PAR2 is activated by trypsin and trypsin-like enzymes. Nystedt et al. (1994) Proc. Natl. Acad. Sci.
  • PARl-blocking antibodies inhibited human platelet activation triggered by low but not high concentrations of thrombin. Hung et al. (1992a); Brass et al. (1992). These data suggested a role for PARl in activation of human platelets by thrombin but held open the possibility that other receptors might contribute. On contrary, PARl appeared to play no roles in mouse platelet activation. PARl expression was difficult to detect in rodent platelets, and PAR1- activating peptides did not activate rodent platelets. Moreover, platelets from PAR1- deficient mice responded like wild-type platelets to thrombin.
  • PAR3 expressed in mouse platelets but could not be detected in human platelets. Ishihara et al. (1997); Kahn et al. (1999) J. Clin. Invest. 103 :879-887. Inhibition of PAR3 function with antibodies that bound to PAR3's hirudin-like domain or by gene knockout prevented mouse platelet activation triggered by low but not high concentrations of thrombin. Kahn et al. (1998); Ishihara et al. (1998) Blood 91 :4152-4157. These results established that PAR3 is necessary for normal thrombin signaling in mouse platelets but also pointed to the existence of another platelet thrombin receptor. Such a receptor, PAR4, was recently identified.
  • PARl amino terminus unmasked by receptor cleavage functions as an agonist for PARl and activates the receptor independently of thrombin and proteolysis.
  • Such peptides have been used as pharmacological probes of PARl function in various cell types, as well as a starting point for PARl antagonist development. Bematowicz et al. (1996) J. Med. Chem. 39:4879-4887; Andrade-Gordon et al. (1999) Proc. Natl Acad. Sci.
  • PAR4 is expressed in human platelets along with PARl .
  • Kahn et al. (1998); Xu et al. (1998); Kahn et al. (1999).
  • PAR4 is activated when thrombin cleaves its amino terminal exodomain at the R47/G48 peptide bond to unmask the tethered ligand GYPGQV.
  • Kahn et al. (1998); Xu et al. (1998).
  • the synthetic peptide GYPGQV functions as an agonist for PAR4 at a concentration of 200-500 ⁇ M.
  • PAR4 activation is not necessary for robust responses in human platelets when PARl function is intact.
  • PAR4 might allow platelets to respond to proteases other than thrombin, mediate thrombin signaling to distinct effectors or with a tempo different from that of PARl, or function in platelet responses beyond simple secretion and aggregation.
  • the existence of two genes and gene products also raises the possibility of differential regulation at many levels in platelets or other cell types. Most interestingly, it is possible that PARs interact with each other.
  • Endothelial activation promotes both neutrophil and platelet adhesion and rolling via stimulation of vWF release and P-selectin expression on the endothelial surface. Subramaniam et al. (1996) Blood 87:1238-1242; Frenette et al. (1996) Cell 84:563-574; Hattori et al. (1989) J Biol. Chem. 264:7768-7771 ; Norman et al. (1995) Blood 86:4417- 4421. Thus, endothelial activation provides a mechanism to concentrate platelets and neutrophils at the same site, perhaps promoting neutrophil-platelet interaction in the setting of graded local inflammatory responses.
  • activated neutrophils might induce platelet activation as a means of further promoting inflammatory cell recruitment by causing release of platelet cytokines, (see Weksler (1988) in Inflammation: Basic Principles and Clinical Correlates (Gallin et al. eds.) p. 543-557, New York), stimulating thrombin generation via platelet procoagulant activity (thereby further activating the endothelium locally), or perhaps inciting local thrombosis to isolate a site of infection.
  • activated neutrophils might bind and activate platelets as a means of promoting their own incorporation into nascent thrombi at sites of injury.
  • activated neutrophils might bind and activate platelets as part of a shutoff mechanism that limits the systemic effects of local inflammation by preventing activated neutrophils from circulating.
  • Experimental models of inflammation in mice may provide a means of testing these hypotheses.
  • Platelet PARs may be exposed to a variety of proteases at sites of inflammation or coagulation, and leukocytes are one potential source.
  • neutrophils and platelets are both concentrated at sites of inflammation and thrombus formation.
  • aggregates of cells containing both neutrophils and platelets have been found in experimental models of inflammation or thrombosis suggesting that interactions between these cell types may be physiologically relevant. Cerletti et al. (1995) Thromb. Haemostas. 74, 218-223.
  • Secreted platelet products act on neutrophils to stimulate adhesion, migration and/or degranulation.
  • Cathepsin G is a neutral serine protease found in neutrophil azurophilic granules and is released upon stimulation of cells by chemotactic agents such as fMet-Leu-Phe (N- formyl-methionyl-leucyl-phenylalanine; fMLP) or platelet activating factor.
  • chemotactic agents such as fMet-Leu-Phe (N- formyl-methionyl-leucyl-phenylalanine; fMLP) or platelet activating factor.
  • protease is known to hydrolyze matrix components such as laminin and fibronectin after methione, leucine, phenylalanine, lysine or arginine residues.
  • Cathepsin G has been found to cause platelet secretion and aggregation ex vivo.
  • ARDS glomerulosclerosis
  • hemostasis thrombosis
  • normal wound healing there is a pressing need for developing therapeutic agents and methods to modulate platelet activation.
  • the invention provides methods for modulating cathepsin G-mediated PAR4 activation and/or platelet activation.
  • the invention provides methods for inhibiting cathepsin G-mediated PAR4 activation comprising contacting any of PAR4, a PAR4 expressing cell, and/or cathepsin G with an agent which interferes with cathespin G/PAR4 interaction, such that PAR4 activation is inhibited.
  • the invention provides methods for inhibiting cathepsin G- mediated PAR4 activation in an individual comprising administering to the individual a composition comprising an agent which interferes with cathepsin G/PAR4 interaction, such that PAR4 activation is inhibited.
  • the invention provides methods of inhibiting PAR4-mediated platelet activation comprising contacting a PAR4 expressing cell (such as platelet) and/or cathepsin G with an agent which interferes with cathepsin G/PAR4 interaction, such that PAR4-mediated platelet activation is inhibited.
  • the invention provides methods of inhibiting PAR4-mediated platelet activation in an individual comprising administering to the individual a composition comprising an agent which interferes with cathepsin G/PAR4 interaction in an amount sufficient to inhibit PAR4-mediated platelet activation.
  • the invention provides methods of inhibiting neutrophil-mediated platelet activation in an individual comprising administering to the individual a composition which inhibits cathepsin G/PAR4 interaction in an amount sufficient to inhibit neutrophil-mediated platelet activation.
  • the invention provides methods of stimulating cathepsin G- mediated PAR4 activation comprising contacting any of PAR4, a PAR4 expressing cell, and/or cathepsin G with an agent which enhances cathepsin G/PAR4 interaction, such that PAR4 activation is stimulated.
  • the invention provides methods of stimulating cathepsin G- mediated PAR4 activation in an individual comprising administering to the individual a composition comprising an agent which enhances cathepsin G/PAR4 interaction, such that
  • the invention provides methods of stimulating PAR4-mediated platelet activation comprising contacting a PAR4-expressing cell and/or cathepsin G with an agent which enhances cathepsin G/PAR4 interaction such that PAR4-mediated platelet activation is stimulated.
  • the invention provides methods of stimulating neutrophil- mediated platelet activation in an individual comprising administering to the individual a composition which enhances cathepsin G/PAR4 interaction in an amount sufficient to stimulate neutrophil-mediated platelet activation.
  • the invention provides screening methods for identifying agents that modulate cathepsin G-mediated PAR4 activation.
  • One in vivo screening method entails the steps of combining at least one agent to be tested with a PAR4-expressing cell and cathepsin G and analyzing at least one characteristic which is associated with modulation of cathepsin G-mediated PAR4 function in the cell, wherein an agent is identified by its ability to elicit at least one such characteristic as compared with control conditions.
  • In vitro screening methods which, inter alia, detect interference with cathepsin
  • G/PAR4 binding are also included in the invention.
  • Figure 1 is a bar graph depicting activation of PARs by thrombin (solid bars) and cathepsin G (gray bars) as measured by calcium release.
  • Figures 2A and 2B are bar graphs depicting effect of serine protease inhibitors on thrombin-induced calcium release (Figure 2A) from Xenopus oocytes that express human PARl (solid bars) or PAR4 (gray bars) and on cathepsin G-induced calcium release (Figure 2B) from Xenopus oocytes that express human PARl (solid bars) or PAR4 (gray bars). The control did not receive any protease inhibitors.
  • Figure 3 is a bar graph depicting effect of thrombin (white bars), cathepsin G (gray bars) and PAR-activating peptides (AP) (solid bars; PARl -activating peptide for PARl mutant and PAR4-activating peptide for PAR4 mutant) on calcium release from Xenopus oocytes that express a mutant PARl (PARl F/A) or a mutant PAR4 (PAR4 G/P).
  • Figures 4 (A) - (C) are graphs depicting calcium mobilization induced by: 100 nM cathepsin G in mammalian cells expressing hPARl ( Figure 4A); 500 nM cathepsin G in mammalian cells expressing hPAR4 ( Figure 4B); 500 nM cathepsin G in untransfected mammalian cells ( Figure 4C).
  • Figures 5 (A) - (H) are graphs depicting agonist-induced calcium mobilization in human platelets loaded with Fura-2 under various conditions. Calcium mobilization induced by 500 nM cathepsin G was measured in na ⁇ ve platelets (Figure 5A), and in platelets treated with 100 ⁇ M PARl -blocking peptide BMS200261 (Figure 5B), 1 mg/ml PAR4-blocking antibody (Figure 5C), or 1 mg/ml pre-immune IgG ( Figure 5D). Responses in platelets desensitized for 30 minutes with 100 ⁇ M SFLLRN ( Figure 5E) or 500 ⁇ M AYPGKF ( Figures 5F, 5G and 5H) were also measured. Agonists were added as indicated by arrows and responses plotted as fluorescence ratio versus time (sec).
  • Figures 6 (A) - (C) are graphs depicting platelet aggregation in: 1 ⁇ M cathepsin G (Figure 6A); and 100 ⁇ M BMS200261 ( Figure 6B); and 1 mg/ml PAR4-blocking antibody (Figure 6C).
  • Figures 7(A) - (C) are graphs depicting neutrophil-dependent calcium mobilization in platelets that were not treated with any antibodies (Figure 7A); in the presence of 1 mg/ml PAR4-blocking antibody (Figure 7B); in the presence of 1 mg/ml pre-immune IgG ( Figure 7C).
  • the arrows indicate the stimulation of platelets with 100 nM fMLP.
  • cathepsin G mediates protease-activated receptor 4
  • PAR4 activation which in turn triggers platelet activation, raising the possibility that cathepsin G mediates neutrophil-platelet interaction at sites of vascular injury or inflammation.
  • This PAR4-specific activation as mediated by cathepsin G, provides useful methods for selective induction or inhibition of platelet activation-associated pathways as well as a basis for discovering useful agents which modulate cathepsin G/PAR4 interaction.
  • inhibition of PAR4 may suppress, disrupt, or prevent neutrophil-platelet interaction, thereby interrupting a positive feedback loop important for the link between coagulation and inflammation. Because PARl signaling would still be intact, PAR4 inhibition would likely not disrupt normal hemostasis.
  • Cathepsin G triggered calcium mobilization in PAR4-transfected fibroblasts, PAR4- expressing Xenopus oocytes and washed human platelets.
  • An antibody raised against the PAR4 thrombin cleavage site blocked platelet activation by cathepsin G but not other agonists. Desensitization with a PAR4 activating peptide had a similar effect. By contrast, inhibition of PARl function had no effect on platelet responses to cathepsin G.
  • the invention provides methods based on these discoveries: (a) modulation of PAR4 activation (including interfering, inhibiting, stimulating or enhancing) by modulating the interaction of PAR4 with cathepsin G; (b) activation of PAR4 by interaction with cathepsin G; (c) modulating neutrophil-mediated platelet activation via cathepsin G/PAR4 interaction; (d) screening methods to identify agents which modulate cathepsin G-mediated PAR4 activation.
  • agents whether agonists or antagonists, could be useful, as they would presumably mediate platelet activation specifically through PAR4 (as opposed to through PARl). This inhibition of platelet activation could be especially useful in the context of, for example, inflammation, thrombosis, or reperfusion injury.
  • Protease-activated receptor 4", "PAR4", “PAR4 receptor” and the like refer to all or part of a vertebrate cell surface protein which is specifically activated by thrombin or a thrombin agonist or cathepsin G thereby activating PAR4 mediated signaling events (effector functions).
  • PAR4 is characterized as having any one or more of the properties (including the agonist activating and the antagonist inhibiting properties) associated with PAR4 function (such as effector functions, as described herein) known in the art. described herein and in US Application No. 09/032,397 and 09/360,482; Kahn et al. (1998); Xu et al.
  • PAR4 may refer to a naturally occurring form of the receptor and/or a recombinantly produced form of the receptor (or, when suitable, a fragment thereof).
  • the term may include variants of PAR4 that retain the at least one activity and/or property of naturally-occurring PAR4.
  • a "functionally preserved” variant or “functionally equivalent” variant of PAR4 is a PAR4 sequence which retains at least one aspect of PAR4 function.
  • Functionally preserved variants may arise, for example, by conservative and/or non-conservative amino acid substitutions, amino acid analogs, and deletions.
  • the function that it preserved depends upon the relevant function being considered.
  • a PAR4 polypeptide is considered for its ability to bind to a particular entity (such as an cathepsin G or other serine protease), then the ability of a variant sequence to encode a polypeptide with equivalent binding characteristics that is relevant.
  • PAR4 function refers to any activity or characteristic associated with expression of PAR4 (including one or more effector activities). These activities and characteristics include, but are not limited to, binding other proteins (particularly serine proteases), regulation (whether induction or repression) of certain genes, and particular phenotypic characteristics of activation, such as calcium efflux, phosphoinositide hydrolysis, and platelet aggregation. These activities and characteristics will be described in more detail below. Because PAR4 exerts control over a number of other genes, it is understood that the term “PAR4 function” encompasses results and characteristics that stem from PAR4 activation which include affecting gene expression of any gene(s) that is regulated by PAR4 gene product or an active fragment thereof.
  • a characteristic which is associated with a "modulation of PAR4 function” is a characteristic which is associated with an alteration or change in PAR4 function.
  • the modulation can be an increase or decrease. Decrease may range from partial to total loss, or knockout, of PAR4 function.
  • Modulation of PAR4 function can occur as a result of an effect at any point along any pathway in which PAR4 exerts control, from transcription of the PAR4 gene, to PAR4 expression (i.e., transcription and/or translation), to affecting regulation of any gene(s) under PAR4 control, to activity associated with regulation of these gene(s).
  • PAR4 functions are described above and herein.
  • the measurable effector functions such as intracellular calcium mobilization, phosphoinositide hydrolysis, and change in cell morphology are a result of intermediate steps, activities, and/or cascades.
  • Cathepsin G refers to an intact cathepsin G molecule or a fragment or region of cathepsin G which is able to bind to PAR4 and initiate one or more effector functions of PAR4.
  • Cathepsin G includes any variants which exhibit the requisite function.
  • a fragment or derivative of cathepsin G which is said to be an antagonist or inhibitor of cathepsin G/PAR4 interaction is a fragment or derivative which inhibits cathepsin G- mediated PAR4 activation.
  • PAR4 activation refers to a state in which PAR4 is able to cause one or more PAR4-mediated effector functions, which are known in the art and described herein.
  • PAR4/cathepsin G interaction refers to any aspect of this interaction, such as binding (which may be due to direct binding of cathepsin G to PAR4 and/or due to involvement of other intermediate moieties), cleavage, and one or more effector functions caused by this interaction.
  • Cathepsin G/PAR4 interaction also includes upstream aspects and events which affect cathepsin G binding to PAR4 and its subsequent activation. For example, lowering the effective amount (biologically available) cathepsin G by, for instance, suppressing cathepsin G release from a cell affects cathepsin G/PAR4 interaction.
  • polypeptide oligopeptide
  • peptide protein
  • polymers of amino acids of any length may be linear or branched, it may comprise modified amino acids, it may be interrupted by non-amino acids, and it may be assembled into a complex of more than one polypeptide chain.
  • the terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component.
  • polypeptides containing one or more analogs of an amino acid including, for example, unnatural amino acids, etc.
  • polypeptides of this invention are based upon an antibody, the polypeptides can occur as single chains or associated chains.
  • a polypeptide "fragment” (also called a "region") of PAR4 (or a "PAR4 fragment” or “PAR4 region”) is a polypeptide comprising an amino acid sequence of PAR4 that has at least about any of the following lengths of contiguous amino acids of a sequence of PAR4:
  • a PAR4 fragment may be characterized as having any of the following functions: (a) ability to bind another protein, particularly a serine protease; (b) ability to elicit a humoral and/or cellular immune response; (c) ability to regulate (i.e., repress or induce) another gene in the pathway regulated by PAR4; (d) ability to elicit a characteristic associated with PAR4 activation.
  • a “fusion polypeptide” is a polypeptide comprising regions in a different position than occurs in nature. The regions may normally exist in separate proteins and are brought together in the fusion polypeptide, or they may normally exist in the same protein but are placed in a new arrangement in the fusion polypeptide. A fusion polypeptide may also arise from polymeric forms, whether linear or branched.
  • polynucleotide and “nucleic acid”, used interchangeably herein, refer to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. These terms include a single-, double- or triple-stranded DNA, genomic DNA, cDNA, RNA, DNA-RNA hybrid, or a polymer comprising purine and pyrimidine bases, or other natural, chemically, biochemically modified, non-natural or derivatized nucleotide bases.
  • the backbone of the polynucleotide can comprise sugars and phosphate groups (as may typically be found in RNA or DNA), or modified or substituted sugar or phosphate groups.
  • the backbone of the polynucleotide can comprise a polymer of synthetic subunits such as phosphoramidates and thus can be a oligodeoxynucleoside phosphoramidate (P-NH2) or a mixed phosphoramidate- phosphodiester oligomer.
  • P-NH2 oligodeoxynucleoside phosphoramidate
  • a phosphorothiate linkage can be used in place of a phosphodiester linkage.
  • a double-stranded polynucleotide can be obtained from the single stranded polynucleotide product of chemical synthesis either by synthesizing the complementary strand and annealing the strands under appropriate conditions, or by synthesizing the complementary strand de novo using a DNA polymerase with an appropriate primer.
  • polynucleotides a gene or gene fragment, exons, introns, mRNA, tRNA, rRNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers.
  • the polynucleotide is DNA.
  • DNA includes not only bases A, T, C, and G, but also includes any of their analogs or modified forms of these bases, such as methylated nucleotides, internucleotide modifications such as uncharged linkages and thioates, use of sugar analogs, and modified and/or alternative backbone structures, such as polyamides.
  • a nucleotide is said to "encode” a polypeptide if, in its native state or when manipulated by methods well known to those skilled in the art, it can be transcribed and/or translated to produce the polypeptide or a fragment thereof.
  • the anti-sense (or complementary) strand of such a polynucleotide is also said to encode the sequence; that is, a polynucleotide sequence that "encodes" a polypeptide includes both the conventional coding strand and the complementary sequence (or strand).
  • “Naturally occurring” or “native” refers to an endogenous polynucleotide or polypeptide sequence, i.e., one found in nature. The term includes alleles and allelic forms of the encoded protein, as well as full-length as processed polynucleotides and polypeptides. Processing can occur in one or more steps, and these terms encompass all stages of processing. Conversely, a “non-naturally occurring" sequence refers to all other sequences, i.e., ones which do not occur in nature, such as recombinant sequences.
  • Recombinant as applied to a polynucleotide or gene, means that the polynucleotide is the product of various combinations of cloning, restriction and/or ligation steps, and other procedures that result in a construct that is distinct from a polynucleotide found in nature.
  • degenerate nucleotide sequence denotes a sequence of nucleotides that includes one or more degenerate codons (as compared to a reference polynucleotide molecule that encodes a polypeptide). Degenerate codons contain different triplets of nucleotides, but encode the same amino acid residue (i.e., GAU and GAC triplets each encode Asp).
  • Transformation or “transfection” refers to the insertion of an exogenous polynucleotide into a host cell, irrespective of the method used for the insertion, for example, lipofection, transduction, infection or electroporation.
  • the exogenous polynucleotide may be maintained as a non-integrated vector, for example, a plasmid, or alternatively, may be integrated into the host cell genome.
  • an “isolated” or “purified” polynucleotide, polypeptide, antibody or cell is one that is substantially free of the materials with which it is associated in nature.
  • substantially free is meant at least 50%, preferably at least 70%, more preferably at least 80%, and even more preferably at least 90% free of the materials with which it is associated in nature.
  • an "isolated" polynucleotide or polypeptide also refers to recombinant polynucleotides or polypeptides, which, by virtue of origin or manipulation: (1) are not associated with all or a portion of a polynucleotide or polypeptide with which it is associated in nature, (2) are linked to a polynucleotide or polypeptide other than that to which it is linked in nature, or (3) does not occur in nature, or (4) in the case of polypeptides arise from expression of recombinant polynucleotides.
  • a “vector” is a self-replicating nucleic acid molecule that transfers an inserted nucleic acid molecule into and/or between host cells.
  • the term includes vectors that function primarily for insertion of a nucleic acid molecule into a cell, replication of vectors that function primarily for the replication of nucleic acid, and expression vectors that function for transcription and or translation of the DNA or RNA. Also included are vectors that provide more than one of the above functions.
  • “Expression vectors” are defined as polynucleotides which, when introduced into an appropriate host cell, can be transcribed and translated into a polypeptide(s).
  • An "expression system” usually connotes a suitable host cell comprised of an expression vector that can function to yield a desired expression product.
  • a “cell line” or “cell culture” denotes eukaryotic cells, derived from higher, multicellular organisms, grown or maintained in vitro. It is understood that the descendants of a cell may not be completely identical (either morphologically, genotypically, or phenotypically) to the parent cell. Cells described as “uncultured” are obtained directly from a living organism, and are generally maintained for a limited amount of time away from the organism (i.e., not long enough or under conditions for the cells to undergo substantial replication).
  • a “host cell” includes an individual cell or cell culture which can be or has been a recipient for vector(s) or for incorporation of nucleic acid molecules and/or proteins.
  • Host cells include progeny of a single host cell, and the progeny may not necessarily be completely identical (in morphology or in genomic of total DNA complement) to the original parent cell due to natural, accidental, or deliberate mutation.
  • a host cell includes cells transfected in vivo with a polynucleotide(s) of this invention.
  • a "biological sample” encompasses a variety of sample types obtained from an individual and can be used in a diagnostic or monitoring assay.
  • the definition encompasses blood and other liquid samples of biological origin, solid tissue samples such as a biopsy specimen or tissue cultures or cells derived therefrom, and the progeny thereof.
  • the definition also includes samples that have been manipulated in any way after their procurement, such as by treatment with reagents, solubilization, or enrichment for certain components, such as proteins or polynucleotides.
  • biological sample encompasses a clinical sample, and also includes cells in culture, cell supernatants, cell lysates, serum, plasma, biological fluid, and tissue samples.
  • a “reagent” polynucleotide, polypeptide, or antibody is a substance provided for a reaction, the substance having some known and desirable parameters for the reaction.
  • a reaction mixture may also contain a "target", such as a polynucleotide, antibody, polypeptide, or assembly of polypeptides that the reagent is capable of reacting with.
  • a target such as a polynucleotide, antibody, polypeptide, or assembly of polypeptides that the reagent is capable of reacting with.
  • the presence and/or amount of the target in a sample is determined by adding a reagent, allowing the reagent and target to react, and measuring the amount of reaction product (if any).
  • a "target” may also be a cell, collection of cells, tissue, or organ that is the object of an administered substance, such as a pharmaceutical compound.
  • the term "agent” means a biological or chemical compound such as a simple or complex organic or inorganic molecule, a peptide, a protein or an oligonucleotide.
  • a vast array of compounds can be synthesized, for example oligomers, such as oligopeptides and oligonucleotides, and synthetic organic compounds based on various core structures, and these are also included in the term "agent".
  • various natural sources can provide compounds for screening, such as plant or animal extracts, and the like. Compounds can be tested singly or in combination with one another.
  • An agent that "inhibits or suppresses PAR4 activation” is an agent that reduces the extent of PAR4 activation mediated by cathepsin G (i.e., the extent of activation of PAR4 in the presence of agent and cathepsin G is reduced when compared to the extent of activation in the presence of cathepsin G without presence of agent).
  • the inhibition or suppression of PAR4 activation may be partial or total.
  • Methods of indicating PAR4 activation are known in the art and are described herein.
  • the inhibition is specific for PAR4, i.e., the effect is greater with respect to PAR4 than with respect to PARl .
  • Assays for determining specificity are known in the art.
  • agents which inhibit PAR4 activation include, but are not limited to, antibodies that block PAR4 cleavage by cathepsin G; agents which bind PAR4 and block tethered ligand binding and/or transmembrane signaling; agents which are cathepsin G inhibitors.
  • an agent that "inhibits or suppresses platelet activation” is an agent that reduces the extent of platelet activation mediated by cathepsin G (i.e., the extent of platelet activation in the presence of agent and cathepsin G is reduced when compared to the extent of activation in the presence of cathepsin G without presence of agent).
  • the inhibition or suppression of platelet activation may be partial or total. Methods of indicating platelet activation are known in the art and are described herein.
  • the inhibition is specific for PAR4, i.e., the effect is greater with respect to PAR4 than with respect to PARl. Examples include, but are not limited to, agents which inhibit activation of cathepsin G.
  • dipeptidyl peptidase I is necessary for generating active cathepsin.
  • An inhibitor of this peptidase (or an inhibitor that suppresses binding of this peptidase to cathepsin G) could suppress or prevent cathepsin G from becoming biologically active (biologically available), thereby suppressing or preventing neutrophil-dependent platelet activation via PAR4.
  • An agent or substance is said to be “selective” or “specific” if it reacts or associates more frequently, more rapidly, with greater duration and/or with greater affinity with a particular cell or substance than it does with alternative cells or substances.
  • an antibody "specifically binds" to a target if it binds with greater affinity, avidity, more readily, and/or with greater duration than it binds to other substances.
  • An agent that "mimics" cathepsin G or a “mimic” or “mimetic” of cathepsin G is a substance which binds and activates PAR4. Further, and preferably, a mimic of cathepsin G fails to significantly stimulate PARl activation.
  • An agent that "suppresses or inhibits” or “interferes with” cathepsin G/PAR4 interaction is an agent which reduces the extent of cathepsin G-mediated PAR4 activation compared to otherwise same conditions except for absence of the agent(s). The inhibition or reduction can be partial or total. It is understood that an agent that interferes with cathepsin G/PAR4 interaction can act on any one or more biological levels which reduces the amount of bioavailable cathepsin G with respect to PAR4 activation.
  • Bioavailable cathepsin G means the local amount of cathepsin G (i.e., the amount of cathepsin G in proximity to a PAR4 receptor) that, when contacted with PAR4, binds to and activates PAR4.
  • an agent which interferes with cathepsin G/PAR4 interaction can cause any of the following: (a) reduction in cathepsin G-encoding RNA (for example, an antisense transcript, which can be a partial anti-sense oligomer or full-length transcript); (b) reduction in the amount of active cathepsin G (for example, an agent which interferes with an enzyme which activates cathepsin G); (c) reduction in amount of cathepsin G which is translated; (d) reduction in local amounts of cathepsin G (with respect to PAR4), effected by, for example, suppression of cathepsin release from a cell such as a neutrophil; (e) decreases cathepsin G half-life.
  • cathepsin G-encoding RNA for example, an antisense transcript, which can be a partial anti-sense oligomer or full-length transcript
  • reduction in the amount of active cathepsin G for example, an agent which interferes with an enzyme which
  • an agent which "enhances" cathepsin G/PAR4 interaction is one which increases such interaction.
  • Such an agent either mimics the action of cathepsin G (i.e., acts as a substitute for cathepsin G) or increases the effect of cathepsin G, with respect to binding to and activating PAR4.
  • an agent which enhances cathepsin G/PAR4 interaction may cause any of the following: (a) increase in cathepsin G-encoding RNA; (b) increase (local) amount of active cathepsin G (by, for example, increasing amount and/or activity of an enzyme that activates cathepsin G); (c) increase in amount of cathepsin G which is translated; (d) increase in local amounts of cathepsin G, such as effected by, for example, an agent which promotes or stimulates cathepsin G release from a cell such as a neutrophil; (e) increases cathepsin G half-life.
  • Agent which "increases cathepsin G activity" is an agent which effects any one of following: (a) increase in cathepsin G-encoding RNA; (b) increase in amount of cathepsin G which is translated; (c) increase in amount of active cathepsin G (such as by enzymatic cleavage or other modification); (d) increase in amount of cathepsin G by stimulating release of cathepsin G from cells; (e) increase of half-life of cathepsin G.
  • a “PAR4-expressing cell” is a cell which produces PAR4, preferably in a form such that PAR4 is able to bind to cathepsin G (in the absence of any agents which inhibit cathepsin G/PAR4 interaction) and initiate one or more PAR4-mediated effector functions.
  • Examples of PAR4-expressing cells (which may be recombinant or naturally-occurring) are known in the art and described herein.
  • An agent or substance (or composition comprising an agent or substance) that increases an activity or other measurable phenotypic characteristic preferably increases that activity or other measurable phenotype by at least about any of the following as compared to control conditions: 1.5 fold, 2-fold, 5-fold, 10-fold increase.
  • An agent or substance (or composition comprising an agent or substance) that decreases or reduces an activity or other measurable phenotypic characteristic preferably decreases that activity or phenotypic characteristic to about the following percentages or less than about any of the following percentages as compared to control conditions: 80%, 50% , 25%, 10%.
  • reporter gene is a polynucleotide sequence that encodes for a detectable product (“reporter”).
  • the reporter gene may encode all or a portion of a detectable product.
  • Examples of reporter genes are known in the art, and include genes whose products give rise to luminescence, such as luciferase, aequorian, ⁇ -galactosidase, chloramphenicol acetyl transferase (CAT), as well as genes whose produces provide a basis for selection, such as an antibiotic resistance gene.
  • “Operably linked” or “operatively linked” refers to a juxtaposition, wherein the components so described are in a relationship permitting them to fimction in their intended manner.
  • a transcriptional regulatory sequence or element is operably linked to a coding sequence is the TRE promotes or allows transcription of the coding sequence.
  • An operably linked TRE is generally joined in cis with the coding sequence, but it is not necessarily contiguous with or directly adjacent to it.
  • an "agonist” refers a molecule which mimics a particular activity, such as a ligand, or interaction of cathepsin G or PAR4 which activates PAR4 thereby triggering the biological events which normally result from the interaction (e.g., phosphoinositide hydrolysis, Ca efflux, and platelet aggregation).
  • an agonist initiates an increase in receptor activity relative to control assays in the absence of activator or candidate agonist.
  • An agonist may possess the same, less, or greater activity than a naturally-occurring cathepsin G-mediated PAR4 activation.
  • an “antagonist” refers a molecule which blocks or suppresses activation of PAR4 activation as mediated by cathepsin G, thereby suppressing the biological events resulting from such an interaction (e.g., phosphoinositide hydrolysis, Ca 2+ efflux, and platelet ATP secretion, or platelet aggregation).
  • An antagonist may bind to and thereby block the activation of PAR4, as long as this inhibition is specifically due to cathepsin G.
  • an antagonist may bind to cathepsin G and thereby block the activation of PAR4.
  • "Modulating" a characteristic, activity or interaction includes increase or decrease of the characteristic, activity or interaction as compared to control conditions.
  • Stimulating PAR4 activation means an increase in the level of PAR4 activation. Such an increase may be as compared to no activation or as compared to a previously lower level of activation.
  • Stimulating PAR4-mediated platelet activation means an increase in the level of platelet activation. Such an increase may be as compared to no activation, or may be an increase as compared to a previously lower level of activation. Methods of indicating platelet activation are known in the art and are described herein.
  • treatment means obtaining a desired pharmacologic and/or physiologic effect.
  • the effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof and/or may be therapeutic in terms of a partial or complete cure for a disease and/or adverse effect attributable to the disease.
  • Treatment covers any treatment of a disease in an individual, preferably a mammal, particular a human, and includes:
  • an “effective amount” is an amount sufficient to effect beneficial or desired clinical results.
  • An effective amount can be administered in one or more administrations.
  • an effective amount of a modulator(s) is an amount sufficient to modulate cathepsin-mediate PAR4 activation and/or platelet activation.
  • an “effective amount” of a modulator (s) is an amount sufficient to palliate, ameliorate, stabilize, reverse, slow or delay progression of a PAR4-associated disease state (i.e., a state in which PAR4 indicate potential or actual pathology).
  • Detection and measurement of indicators of efficacy are generally based on measurement of PAR4 and/or clinical symptoms associated with the disease state, such as heart attack, stroke, atherosclerosis, restemosis, pulmonary inflammation (ARDS), and glomerulosclerosis, and with the disorders in such as, but not limited to, hemostasis, thrombosis, and normal wound healing.
  • An "individual” is a vertebrate, preferably a mammal, more preferably a human.
  • Mammals include, but are not limited to, farm animals, sport animals, primates, rodents and pets.
  • compositions comprising one or more of these substances.
  • compositions may further comprise suitable excipients, such as pharmaceutically acceptable excipients including buffers, which are well known in the art.
  • the invention provides methods of inhibiting, or suppressing, PAR4 activation, particularly, cathepsin G-mediated PAR4 activation.
  • these methods entail contacting PAR4 and/or cathepsin G with an agent that interferes with cathepsin G/PAR4 interaction, such that cathepsin G-mediated activation of PAR4 is inhibited.
  • an agent that interferes with cathepsin G/PAR4 interaction is administered to an individual in an amount sufficient to inhibit cathepsin G-mediated PAR4 activation.
  • any agent which inhibits cathepsin G/PAR4 interaction such that cathepsin G- mediated PAR4 activation is inhibited is suitable.
  • an agent other than a PAR4 antagonist is used. Determining that an agent inhibits cathepsin G/PAR4 interaction may be determined using standard techniques in the art. For example, PAR4 activation is measured in the presence of cathepsin G (controlling for other sources of possible PAR4 activation, such as thrombin), with and without agent. A reduction in level of activation in the presence of agent under these reaction conditions indicates that the agent specifically inhibits cathepsin G-mediated PAR4 activation.
  • Agents which inhibit cathepsin G are known, as are agents which inhibit PAR4 (such as an anti-PAR4 antibody which inhibits binding of cathepsin G).
  • agents which inhibit cathepsin G include, but are not limited to, ecotin, AMCI-1, AMCI-2, AMCI-3, oxidized mucus proteinase inhibitor (MPI), squamous cell carcinoma antigen 2 (SCCA2), suramin, alpha 1- antichymotrypsin, alpha 1 -proteinase inhibitor, eglin c, squash inhibitors, sulfated polymer MDL 101,028. Bania et al. (1999) Eur. J. Biochem. 262:680-687; Boudier et al.
  • cathepsin G Another example of an inhibitor of cathepsin G is fragment or derivative of cathepsin G which inhibits cathepsin G-mediated PAR4 activation, i.e., competes with intact cathepsin G for binding to PAR4 but does not activate PAR4, or causes reduction in extent of activation of PAR4.
  • an agent which inhibits cathepsin G is an antibody (For example, the antibody binds to cathepsin G such that cathepsin G binding to and/or cleavage of PAR4 is impaired.).
  • agents which inhibit PAR4 include, but are not limited to, anti- PAR4 antibodies which block binding and cleavage by cathepsin G. Methods of producing antibodies and testing for such specificity are well known in the art.
  • the antibody is homogeneous with respect to sequence (for example, is monoclonal). It is understood, however, that for the practice of these methods, the inhibitor specifically inhibits cathepsin G/PAR4 interaction, which can be shown using standard methods in the art. For example, using a culture system an assay is conducted with and without cathepsin G, using cells which do or do not express PAR4 (by, for example, transfection with a
  • suppression of cathepsin G-mediated PAR4 activation is effected by an agent which reduces cathepsin G activity by reducing the amount of cathepsin G available for interacting with PAR4.
  • an agent could reduce the amount of bioavailable cathepsin G by inhibiting the amount of cathepsin G (either by inhibiting transcription and or translation of cathepsin G mRNA or by decreasing half-life).
  • an agent could inhibit activation of cathepsin G such as by dipeptidyl peptidase I.
  • an agent could inhibit release of cathepsin G from a cell, such as from a neutrophil cell.
  • the methods may be in vitro, ex vivo, or in vivo.
  • an agent is contacted with cathepsin G and/or PAR4 (or PAR4-expressing cell) under suitable reaction conditions such that cathepsin G-mediated PAR4 activity is reduced (or would be reduced if cathepsin G were present).
  • PAR4-expressing cells may be used, which are combined with the agent(s).
  • naturally-occurring cells which express PAR4 (or at least produce PAR4 RNA transcripts) include platelets, small intestine, lung, placenta, liver, pancreas, thyroid, prostate, and testis. Xu et al. (1998). In the presence of cathepsin G and the agent, cathepsin G-mediated PAR4 activation is inhibited.
  • PAR4 expressing cells and cathepsin G expressing cells are used.
  • An agent is introduced into the cell culture in an amount sufficient to inhibit cathepsin G-mediated PAR4 activation.
  • the cells are removed from an individual, are contacted with the agent(s), and then are returned to the individual.
  • suitable cells or cell classes are isolated (such as platelets).
  • the agent is administered (in a suitable formulation and dosage) to an individual.
  • a suitable individual for the ex vivo or in vivo methods is one who has a condition and/or disorder which would likely benefit from inhibition of PAR4 activation, such as a thrombosis or inflammation.
  • the individual is human.
  • Administration options are discussed below. Preferred modes of administration are local although non-local methods may be used.
  • Assays and indicia of PAR4 activation are known in the art and described in the Examples.
  • inhibition of PAR4 activation may be measured and/or indicated by several criteria, such as evaluating an appropriate biological sample which contains PAR4 expressing cells, testing hemostatis, and/or other clinical indicia of reduction in extent of PAR4 activation, depending on the individual's condition.
  • the invention also provides methods of inhibiting PAR4-mediated platelet activation.
  • these methods entail contacting PAR4 and/or cathepsin G with an agent that interferes with cathepsin G/PAR4 interaction, such that PAR4-mediated platelet activation is inhibited.
  • PAR4-expressing cells are used, which may be recombinant or naturally-occurring.
  • an agent that interferes with cathepsin G/PAR4 interaction is administered to an individual in an amount sufficient to inhibit PAR4-mediated platelet activation.
  • an agent which inhibits cathepsin G/PAR4 interaction such that platelet activation is inhibited is suitable.
  • an agent is other than a PAR4 antagonist. Determining that an agent inhibits cathepsin G/PAR4 interaction may be determined using standard techniques in the art. For example, PAR4 activation is measured in the presence of cathepsin G (controlling for other sources of possible PAR4 activation, such as thrombin), with and without agent. A reduction in level of activation in the presence of agent under these reaction conditions indicates that the agent specifically inhibits cathepsin G-mediated PAR4 activation.
  • Agents which inhibit cathepsin G are known, as are agents which inhibit PAR4 (such as anti-PAR4 antibody).
  • agents which inhibit cathepsin G include, but are not limited to, ecotin, AMCI-1, AMCI-2, AMCI-3, oxidized mucus proteinase inhibitor (MPI), squamous cell carcinoma antigen 2 (SCCA2), suramin, alpha 1 -antichymotrypsin, alpha 1 -proteinase inhibitor, eglin c, squash inhibitors, sulfated polymer MDL 101 ,028.
  • Another example of an inhibitor of cathepsin G is fragment or derivative of cathepsin G which inhibits cathepsin G-mediated PAR4 activation or an appropriate anti-cathepsin G antibody, as described above.
  • the antibody is homogeneous with respect to sequence (for example, is monoclonal).
  • agents which inhibit PAR4 include, but are not limited to, anti-PAR4 antibodies (particularly, but not necessarily, those which block the PAR4 thrombin/cathepsin G cleavage site).
  • suppression of PAR4-mediated platelet activation is effected by an agent which reduces cathepsin G activity by reducing the amount of cathepsin G available for interacting with PAR4.
  • an agent which reduces cathepsin G activity by reducing the amount of cathepsin G available for interacting with PAR4.
  • such an agent could reduce the amount of bioavailable cathepsin G by inhibiting the amount of cathepsin G (either by inhibiting transcription and/or translation of cathepsin G mRNA or by decreasing half-life).
  • an agent could inhibit dipeptidyl peptidase I-mediated activation of cathepsin G.
  • the methods may be in vitro, ex vivo, or in vivo.
  • an agent is contacted with cathepsin G and/or a PAR4 expressing cell (whether recombinant or naturally-occurring).
  • the three components are combined under suitable reaction conditions such that PAR4-mediated platelet activation is reduced.
  • PAR4- expressing cells may be used, which are combined with the agent(s).
  • platelet activation mediated by cathepsin G is inhibited.
  • the cells are removed from an individual, are contacted with the agent(s), and then are returned to the individual.
  • suitable cells or cell classes are isolated
  • the agent is administered (in a suitable formulation and dosage) to an individual.
  • a suitable individual for the ex vivo or in vivo methods is one who has a condition and/or disorder which would likely benefit from inhibition of PAR4 activation, such as a thrombosis or inflammation.
  • the individual is human. Administration options are discussed below.
  • Preferred modes of administration are local although non-local methods may be used.
  • Assays and indicia of platelet activation are known in the art and described in the Examples.
  • inhibition of platelet activation may be measured and/or indicated by several criteria, such as evaluating an appropriate biological sample which contains PAR4 expressing cells, testing hemostatis and/or other clinical indicia of reduction in extent of platelet activation, depending on the individual's condition.
  • the invention also provides methods of inhibiting neutrophil-mediated platelet activation in an individual, comprising administering to the individual a composition comprising an agent which inhibits cathepsin G-PAR4-mediated platelet activation in an amount sufficient to inhibit cathepsin G-PAR 4-mediated platelet activation.
  • suitable agents which include agents which inhibit cathepsin G/PAR4 interaction, been described above.
  • these methods are designed for settings in which neutrophils are found in significant concentrations, generally these methods entail administering the composition such that the agent(s) will reach these site(s), and the individuals will have a condition(s) in which neutrophil-mediated platelet activation is perceived to be, or believed to be, an undesirable occurrence.
  • the individual may have a condition in which significant neutrophil margination occurs or may occur, such as sepsis, endotoxic shock, infarction due to microvascular thrombosis and tissue damage, and reperfusion injury.
  • the methods can be used to treat, delay and/or prevent such a condition(s).
  • formulations and administration protocols can be used, from topical to systemic (such as IN.).
  • the invention provides methods of stimulating PAR4 activation using cathepsin G, comprising contacting PAR4, (e.g., a PAR4-expressing cell) with cathepsin G (or a composition comprising cathepsin G) in an amount sufficient to effect stimulation of PAR4 activation.
  • PAR4 is contacted with an agent that mimics cathepsin G (or a composition comprising such a mimic (or mimetic)).
  • cathepsin G is induced such that the amount of biologically available (or biologically active) cathespin G is increased (for example, the activity of cathepsin G is increased and/or amount of cathepsin G release from cells is increased).
  • PAR4-expressing cells are used, which may be recombinant or naturally-occurring.
  • a composition comprising cathepsin G or a mimetic of cathepsin G is administered to an individual in an amount effective to stimulate PAR4 activation.
  • mimics of cathepsin G are peptides which activate PAR4, such as AYPGKF and GYPGQV (for GYPGQV, see Kahn et al. (1998); Xu et al. (1998)).
  • the invention provides methods of stimulating P AR4 activation using AYPGKF.
  • AYPGKF is contacted with a PAR4 expressing cell, whereby PAR4 is activated.
  • AYPGKF is administered to an individual in an amount sufficient to stimulate PAR4 activation.
  • agents which increase (biologically available or active) cathepsin G is dipeptidyl peptidase I (Pham et al. (1999)), fMLP and other neutrophil activators which cause cathepsin G release.
  • the mimic of cathepsin G is other than a
  • PAR4 activating peptide such as AYPGKF and GYPGQV.
  • cathepsin G or an mimic of cathepsin G
  • a cell expressing PAR4 whether naturally occurring or recombinant, such as those described herein and in the examples.
  • the cells are removed from an individual, are contacted with cathepsin G (or an mimic of cathepsin G), and then are returned to the individual.
  • cathepsin G (or an mimic of cathepsin G) is administered (in a suitable formulation and dosage) and/or cathepsin G is induced by adding an agent which elicits cathepsin G production or otherwise enhances cathepsin G activity, such as fMLP (via promoting cathepsin G release) and dipeptidyl peptidase I.
  • an agent which elicits cathepsin G production or otherwise enhances cathepsin G activity such as fMLP (via promoting cathepsin G release) and dipeptidyl peptidase I.
  • a suitable individual for the ex vivo or in vivo methods is one who has a condition and/or disorder which would likely benefit from PAR4 activation, such as a wound, improper or inappropriate hemostasis response (e.g., a bleeding condition), or a condition in which an enhanced and/or localized inflammatory response is desirable.
  • Administration options are discussed below.
  • Preferred modes of administration are local (such as directly to the wound), although non-local methods may be used.
  • the amount(s) to be administered depends, inter alia, on the condition to be treated as well as the agent to be used.
  • An agent (or composition comprising one or more agents) is administered (which could occur in one or more administrations) in a sufficient amount to achieve the desired result, which may be any manifestation of PAR4 activation.
  • Assays and indicia of PAR4 activation (such as calcium efflux and platelet activation) are known in the art and described in the Examples.
  • the invention also provides methods of stimulating PAR4-mediated platelet activation comprising contacting PAR4 (e.g., a PAR4-expressing cell) with cathepsin G (or mimic of cathepsin G) in an amount sufficient to effect activation of platelets.
  • PAR4-expressing cells are used, which may be recombinant or naturally- occurring.
  • a composition comprising cathepsin G or a mimetic of cathepsin G is administered to an individual in an amount effect to stimulate PAR4- mediated platelet activation.
  • a composition comprising an agent which stimulates cathepsin G production, activation and/or release in cells is administered.
  • the cathepsin G mimic is other than a PAR4 activating peptide.
  • the invention provides methods of stimulating PAR4-mediated platelet activation using AYPGKF. For these methods, AYPGKF is contacted with a PAR4 expressing cell (such as a platelet), thereby stimulating stimulation of PAR4-mediated platelet activation. In other embodiments, AYPGKF is administered to an individual in an amount sufficient to stimulate PAR4- mediated platelet activation.
  • cathepsin G may be contacted with, for example, a cell expressing PAR4 (such as those described in the examples).
  • the cells are removed from an individual, are contacted with cathepsin G (or a mimic), and then are returned to the individual.
  • suitable cells or cell classes are isolated (such as platelets).
  • cathepsin G (or a mimic) is administered (in a suitable formulation and dosage) and/or induced by adding an agent which elicits its production or otherwise enhances cathepsin G activity (for example, by stimulating release) such as fMLP.
  • a suitable individual for the ex vivo or in vivo methods is one who has a condition and/or disorder which would likely benefit from PAR4 activation, such as a wound, improper or inappropriate hemostasis response (e.g., a bleeding condition), or a condition in which an enhanced and/or localized inflammatory response is desirable.
  • Administration options are discussed below.
  • Preferred modes of administration are local (such as directly to the wound), although non-local methods may be used.
  • platelet activation is stimulated by stimulating neutrophil production (in an individual or ex vivo or in vitro) and/or introducing neutrophils to an individual.
  • Other embodiments include the additional step of adding (or administering) an agent which stimulates cathepsin G release, such as fMLP.
  • the invention provides methods of stimulating neutrophil-mediated platelet activation in an individual comprising administering to the individual a composition which enhances cathepsin G/PAR4 interaction in an amount sufficient to stimulate neutrophil- mediated platelet activation.
  • agents which include agents which enhance cathepsin G/PAR4 interaction, have been discussed above.
  • compositions may also contain a variety of, for example, other conventional antiplatelet or anti-thrombin or anti-cathepsin G compounds.
  • the most widely used antiplatelet agent is aspirin, a cyclooxygenase inhibitor. Although aspirin blocks ADP- and collagen-induced platelet aggregation, it fails to prevent cyclooxygenase- independent platelet aggregation initiated by agonists, such as thrombin.
  • Alternative anti- thrombin compounds are hirudin derivatives.
  • compositions may be administered to an individual using any convenient means capable of resulting in the desired modulation.
  • the a composition can be incorporated into a variety of formulations for administration.
  • Compositions can be formulated into pharmaceutical compositions by combination with appropriate, pharmaceutically acceptable carriers or diluents, and may be formulated into preparation in solid, semi-solid, liquid or gaseous forms, such as tablets, capsules, powders, granules, ointments, solutions, transdermal patches, suppositories, injections, inhalants, and aerosols.
  • administration can be achieved in various ways, including oral, buccal, rectal, parenteral, intraperitoneal, intradermal, transdermal, intratracheal, etc., administration.
  • compositions may be administered in the form of their pharmaceutically acceptable salts, or they may also be used alone or in appropriate association, as well as in combination, with other pharmaceutically active compounds.
  • the following methods and excipients are merely exemplary and are in no way limiting.
  • compositions can be used alone or in combination with appropriate additives to make tablets, powders, granules or capsules.
  • additives are conventional additives, such as lactose, mannitol, com starch or potato starch; binders, such as com starch, potato starch or sodium carboxymethylcellulose; lubricants, such as talc or magnesium stearate; and if desired, diluents, buffering agents, moistening agents, preservatives and flavoring agents.
  • compositions can be formulated into preparations for injection by dissolving, suspending or emulsifying them in an aqueous or nonaqueous solvent, such as vegetable or other similar oils, synthetic aliphatic acid glycerides, esters of higher aliphatic acids or propylene glycol. If desired, conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifying agents, stabilizers and preservatives may also be added.
  • concentration of therapeutically active compound in the formulation may vary from about 0.5-100 wt.%.
  • compositions can be utilized in aerosol formulation to be administered via inhalation by using, for example, pressurized acceptable propellants such as dichlorodifluoromethane, propane, nitrogen and the like.
  • compositions can be made into suppositories by mixing with a variety of bases such as emulsifying bases or water-soluble bases for rectal administration.
  • bases such as emulsifying bases or water-soluble bases for rectal administration.
  • the suppository can include vehicles such as cocoa butter, carbowaxes and polyethylene glycols, which melt at body temperature, yet are solidified at room temperature.
  • Unit dosage forms for oral or rectal administration such as syrups, elixirs, and suspensions may be provided wherein each dosage unit (e.g., a teaspoonful, tablespoonful, tablet or suppository) contains a predetermined amount of the composition containing one or more inhibitors.
  • unit dosage forms for injection or intravenous administration may comprise the inhibitor(s) in a composition as a solution in sterile water, normal saline or another pharmaceutically acceptable carrier.
  • the pharmaceutically acceptable excipients such as vehicles, adjuvants, carriers or diluents, are readily available to the public.
  • pharmaceutically acceptable auxiliary substances such as pH adjusting and buffering agents, tonicity adjusting agents, stabilizers, wetting agents and the like, are readily available to the public.
  • Agents for use in the methods of the invention may be any compound displaying requisite activity.
  • they may be small organic compounds having a molecular weight of more than 50 and less than about 2,500 daltons.
  • Candidate compounds comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and may generally include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups.
  • the candidate compounds are also found among biomolecules including, but not limited to: peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivative, stmctural analogs or combinations thereof.
  • compositions may be formulated in a physiologically acceptable carrier, at a dosage suitable to achieve the desired result.
  • the dosage for compounds suppressing cathepsin G-mediated PAR4 activation is such that PAR4 activation is reduced by at least about any of the following: 40%, 50%, 75%, 80%, 90%, 95%.
  • the decrease in degree of PAR4 activation includes, but is not limited to, about any of the following ranges: 50% to 100%; 50% to 90%; 60% to 90%; 75% to 85%; 75% to 90%; 80% to 100%; 80% to 95%; 80% to 90%.
  • Platelet activation may be induced by a number of biological phenomenon, including injury, response to certain compounds, etc.
  • Compositions are generally administered daily, although they may be administered less often, such as bi-weekly, weekly or monthly. With respect to inhibition of platelet activation, compositions are administered in an amount to provide at least about 50%, more preferably at least about 75%), even more preferably at least about 80%, even more preferably at least about 90% decrease in platelet activation. In other embodiments, the decrease in degree of platelet activation includes, but is not limited to, about any of the following ranges: 50% to 100%;
  • the amount may vary with the general health of the patient, the response of the patient to the drug, whether the composition is used by itself or in combination with other drugs, and the like. Daily administrations may be one or more times, usually not more than about four times, particularly depending upon the level of drug which is administered.
  • compositions are particularly useful in the treatment of diseases such as myocardial infarction, stroke, pulmonary embolism, deep vein thrombosis, peripheral arterial occlusion, and other blood thromboses such as microvascular thrombosis and reperfusion injury. Inhibition of platelet activation in such disorders may allow localized treatment at the site of the clotting, thus eliminating some of the more unpleasant side effects of systemic treatment, e.g., hemorrhage. Generally, but not necessarily, the composition(s) will be administered acutely (i.e., upon presentation of the clinical indication), by IN.
  • diseases such as myocardial infarction, stroke, pulmonary embolism, deep vein thrombosis, peripheral arterial occlusion, and other blood thromboses such as microvascular thrombosis and reperfusion injury.
  • Inhibition of platelet activation in such disorders may allow localized treatment at the site of the clotting, thus eliminating some of the more unpleasant side effects of systemic treatment, e.g.,
  • the present invention encompasses methods of identifying agents that modulate cathepsin G-mediated PAR4 activation based on their ability to elicit a characteristic associated with PAR4 function, or activity. These methods, which are useful for identifying agents which may modulate PAR4-specific platelet activation, may be practiced in a variety of embodiments.
  • the methods described herein are in vitro and in vivo screening assays. In the in vitro embodiments, an agent is tested for its ability to modulate function of a cathepsin G- mediated PAR4 activity. In the in vivo embodiments, living cells having PAR4 function are used for testing agents in conjunction with cathepsin G.
  • an agent may be identified on the basis of only partial loss of cathepsin G-mediated PAR4 function, although characteristics associated with total loss of cathepsin G-mediated PAR4 function may be preferable for antagonist.
  • An agent may also be identified by its ability to enhance cathepsin G-mediated PAR4 function.
  • the screening methods of the invention encompass methods of identifying agonists which increase or elicit activation as well as methods of identifying antagonists which inhibit activity.
  • the general screening strategy is to introduce a pharmaceutical candidate and then determine whether the effect (if any) is beneficial, and preferably specific.
  • agent can be direct (such as determining whether a candidate binds to cathepsin G and/or PAR4 polypeptide in the assay) in an in vitro system, but also be used in an in vivo system, such as cell culture.
  • an agent that modulates the activity of cathepsin G/PAR4 interaction has the potential to inhibit a pathology associated with cathepsin G/PAR4 interaction when administered. It is not necessary that the mechanism of modulation be known; only that the alteration affect infected cells preferably without being significantly detrimental to other, uninfected cells.
  • Modulation of cathepsin G-mediated PAR4 activation and/or platelet activation may occur at any level that affects the function of cathepsin G or PAR4 or platelet or any combination thereof.
  • an agent may modulate cathepsin G-mediated PAR4 activation and/or platelet activation by binding to cathepsin G and/or PAR4.
  • An agent may modulate cathepsin G-mediated PAR4 activation and/or platelet activation by preventing, reducing or increasing production of a cathepsin G and/or PAR4 binding protein.
  • An agent may modulate cathepsin G-mediated PAR4 activation and/or platelet activation by binding to a polypeptide that binds cathepsin G and/or PAR4.
  • the assays described herein include those that examine effects on unoccupied receptors as well as assays that utilize displacement of a ligand from an occupied receptor.
  • the agent can be any compound, complex or substance.
  • the choice of agents to be screened is governed by several parameters, such as the particular polynucleotide or polypeptide target, its perceived function, its three-dimensional structure
  • agents which may be used in the screening methods described herein encompass numerous chemical classes.
  • Candidate agents can be obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides and oligopeptides.
  • libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced.
  • natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means, and may be used to produce combinatorial libraries.
  • Known pharmacological compounds may be subjected to directed or random chemical modifications, such as acylation, alkylation.
  • any polynucleotide could be used as an agent, the synthesis of which may be achieved by methods well known in the art.
  • the recombinant DNA molecules may be isolated from a human hematopoetic cDNA library.
  • the synthesis of cDNA libraries and the choice of vector into which the cDNA molecules may be cloned are conventional techniques.
  • (intact) PAR4, functional fragments of PAR4, and/or functional equivalents (including functional equivalent fragments) of PAR4 may be used, as appropriate.
  • cathepsin G binds to a region(s) of PAR4 which may be isolated from intact PAR4, this region(s) may be used for certain studies, such as binding studies. Preparation of polypeptide fragments
  • an agent is screened in an in vitro system, in which an agent is tested for its ability to modulate interaction between cathepsin
  • these in vitro screening assays entail determining whether an agent interferes with binding of cathepsin G to PAR4 using standard techniques in the art.
  • a preliminary indication of whether an agent interferes with cathepsin G/PAR4 interaction is assaying for agents which bind to cathepsin G and/or PAR4.
  • cathepsin G and/or PAR4 is first recombinantly expressed in a prokaryotic or eukaryotic expression system as a native or as a fusion protein in which the full length cathepsin G and/or PAR4 or fragment of cathepsin G and/or PAR4 is conjugated with a well-characterized epitope or protein. Recombinant cathepsin G and or PAR4 is then purified by, for instance, immunoprecipitation using anti-cathepsin G and/or anti-PAR4 antibodies or anti-epitope antibodies or by binding to immobilized ligand of the conjugate.
  • cathepsin G and/or PAR4 are available by other means, such as through commercial sources.
  • An affinity column made of cathepsin G and/or PAR4 or cathepsin G and/or PAR4 fusion protein is then used to screen a mixture of compounds which have been appropriately labeled.
  • Suitable labels include, but are not limited to flurochromes, radioisotopes, enzymes and chemiluminescent compounds.
  • the unbound and bound compounds can be separated by washes using various conditions (e.g. high salt, detergent ) that are routinely employed by those skilled in the art. See, for example, Lechner and Carbon (1991) Cell 64:717-725.
  • a BIAcore assay using a sensor chip (supplied by Pharmacia Biosensor, Stitt et al. (1995) Cell 80: 661-670) that is covalently coupled to native cathepsin G and/or PAR4 or cathepsin G and/or PAR4-fusion proteins, may be performed to determine the cathepsin G and/or PAR4 binding activity of different agents.
  • Similar methods can be used for screening for an agent(s) that competes for binding to cathepsin G and/or PAR4.
  • Competitive assays are known in the art, and generally involve measuring degree of binding in the presence of increasing amounts of the putative competitor.
  • affinity chromatography there are other techniques such as solution based binding systems. Non-specific binding to the affinity column can be minimized by pre-clearing the compound mixture using an affinity column containing merely the conjugate or the epitope.
  • a similar method can be used for screening for agents that compete for binding to cathepsin G and/or PAR4 polypeptides.
  • the in vitro screening methods of this invention include stmctural, or rational, dmg design, in which the amino acid sequence, three-dimensional atomic structure or other property (or properties) of cathepsin G and/or PAR4 provides a basis for designing an agent which is expected to bind to cathepsin G and/or PAR4.
  • the design and/or choice of agents in this context is governed by several parameters, such as the perceived function of the cathepsin G and/or PAR4 target, its three- dimensional stmcture (if known or surmised), and other aspects of rational dmg design.
  • an agent designed and/or obtained by rational dmg designed may also be tested in the in vivo assays described below.
  • In vivo screening methods In in vivo screening assays, a living cell containing a functioning PAR4 gene, or a living cell containing a polynucleotide constmct comprising a PAR4 encoding sequence are exposed to an agent in the presence of cathepsin G under conditions which permit cathepsin G/PAR4 interaction. In contrast (as described above), conventional dmg screening assays have typically measured the effect of a test agent on an isolated component, such as an enzyme or other functional protein.
  • an in vivo screening assay has several advantages over conventional dmg screening assays: 1) if an agent must enter a cell to achieve a desired therapeutic effect, an in vivo assay can give an indication as to whether the agent can enter a cell; 2) an in vivo screening assay can identify agents that, in the state in which they are added to the assay system are ineffective to elicit at least one characteristic which is associated with modulation of cathepsin G-mediated P AR4 function, but that are modified by cellular components once inside a cell in such a way that they become effective agents; 3) most importantly, an in vivo assay system allows identification of agents affecting any component of a pathway that ultimately results in characteristics that are associated with cathepsin G-mediated PAR4 function.
  • screening is performed by adding an agent to a sample of appropriate cells, and monitoring the effect.
  • the experiment preferably includes a control sample which does not receive the candidate agent.
  • the treated and untreated cells are then compared by any suitable phenotypic criteria, which in this instance is any characteristic associated with PAR4 function, including but not limited to intracellular calcium mobilization, phosphoinositide hydrolysis, change in platelet cell shape (morphology) and platelet activation.
  • cathepsin G-mediated modulation of PAR4 is measured, i.e., the modulation must be specific interference, mimicry, and/or enhancement of cathepsin G-mediated PAR4 activation. This specificity may be determined using experimental methods and designs standard in the art.
  • a reaction is conducted using a PAR4 expressing cell (whether naturally- occurring or recombinant) in the presence of agent and cathepsin G; a parallel experiment is conducted using a PAR4 expressing cell in the presence of agent without cathepsin G.
  • a reaction is conducted using a PAR4 expressing cell(s) in the presence of agent; an effect, if any, is compared to conditions in the presence of varying amounts of cathepsin G (or, conversely, in the presence of varying amounts of agent while in the presence of cathespin G).
  • Competition-based assays to establish specificity are known in the art as well as described herein.
  • an assay can be performed with and without cathepsin G using PAR4 expressing cells and cells that do not express PAR4.
  • an assay could be performed in the presence of cathepsin G, and PAR4 cleavage could be monitored using, for instance, an antibody that binds to the
  • PAR4 cleavage site i.e., an antibody which binds to the amino terminal exodomain amino cleavage site.
  • an agent is identified by its ability to elicit a characteristic associated with modulation of cathepsin G-mediated PAR4 function in a suitable host cell.
  • the modulation is an increase or activation of cathepsin G-mediated
  • the modulation is a decrease (which can be partial to total loss) of cathepsin G-mediated PAR4 activation (i.e., the screening methods identify antagonists).
  • the screening methods identify agents which may modulate cathepsin G-mediated PAR4 activation. In some embodiments, the screening methods identify agents which may modulate PAR4-mediated platelet activation (by modulating cathepsin G/PAR4 interaction).
  • the invention provides methods for identifying an agent that may modulate cathepsin G-mediated PAR4 activation comprising the following steps: (a) combining, or contacting, at least one agent to be tested with a PAR4-expressing cell and cathepsin G (i.e., contacting said host cell with cathepsin G in the presence of agent), and (b) analyzing at least one characteristic which is associated with modulation of cathepsin G-mediated PAR4 function in said cell, wherein an agent is identified by its ability to elicit at least one such characteristic, as compared to control conditions (i.e., without agent).
  • the (host) cell may be any cell in which PAR4 function has been demonstrated.
  • PAR4 function may arise due to naturally-occurring PAR4 encoding sequences in the host cell or due to recombinant expression (i.e., expression of recombinant PAR4 sequence).
  • host cells include, but are not limited to, platelet cells, or other suitable host cells, preferably mammalian cells, expressing recombinant PAR4.
  • suitable host cells include, but are not limited to, Xenopus oocytes, COS7 cells, mouse fibroblasts, Ratl cells, HEK 293 cells, CHO cells, CN1 cells, L cells, and HeLa cells.
  • a PAR4-expressing cell may be contacted first with cathepsin G, and then an agent, or the reverse.
  • a PAR4-expressing cell may be simultaneously contacted with agent and cathepsin G.
  • these methods comprise the following steps: (a) introducing a polynucleotide encoding PAR4 into a suitable host cell that otherwise lacks PAR4 function, wherein PAR4 function is restored (or established) in said host cell; (b) combining said host cell with cathepsin G and at least one agent to be tested; and (c) analyzing at least one characteristic which is associated with modulation of PAR4 function, wherein an agent is identified by its ability to elicit at least one said characteristic.
  • PAR 1 -deficient mouse lung fibroblasts that have been stably transfected with cD ⁇ A encoding human PAR4 (KOLF-PAR4) are used for the screening assays.
  • KOLF-PAR4 is incubated with the agent to be screened.
  • the modulating potency of the agents to be screened can be measured by, for example, the intracellular calcium mobilization assay as described in Example 3.
  • the host cell used for these methods initially lacks PAR4 function (i.e., lacks PAR4 function before introduction of polynucleotide encoding PAR4). Lacking PAR4 function may be partial to total.
  • a suitable host cell in this context is any host cell in which recombinant PAR4 complements a defect of host cell PAR4 function.
  • PAR1- deficient mouse lung fibroblasts see Trejo et al. (1996) J Biol. Chem. 271 :21536- 21541; Connolly et al. (1996) Nature 381:516-519
  • KLFs mouse lung fibroblasts
  • Devising host cells that lack PAR4 (or its homologue) function may be achieved in a variety of ways, including, but not limited to, genetic manipulation such as deletion mutagenesis, recombinant substitution of a functional portion of the gene, frameshift mutations, conventional or classical genetic techniques pertaining to mutant isolation, or alterations of the regulatory domains.
  • genetic manipulation such as deletion mutagenesis, recombinant substitution of a functional portion of the gene, frameshift mutations, conventional or classical genetic techniques pertaining to mutant isolation, or alterations of the regulatory domains.
  • host cells derived from certain type of tissues, such as fibroblasts lack PAR4 function. Determination of whether a cell lacks PAR4 function is well within the skill of the art.
  • recombinant PAR4 product can substitute for the host cell's PAR4 (or homologue) gene product
  • the host cell's PAR4 (or homologue) function may be deleted by, for instance, recombinant methods.
  • a polynucleotide encoding PAR4 or a functional fragment thereof, is then introduced into the cell, depending on the particular host cell used, by using any of the many methods known in the art, including but not limited to electroporation, CaCl 2 precipitation, and lipofectamine treatment of the host cells.
  • Polynucleotides introduced into a suitable host cell(s) are polynucleotide constmcts comprising a polynucleotide encoding PAR4 or a functional fragment thereof. These constmcts contain elements (i.e., functional sequences) which, upon introduction of the constmct, allow expression (i.e., transcription, translation, and post-translational modifications, if any) of PAR4 amino acid sequence in the host cell. Exemplary methods and procedures for generating such host cells either transiently or stably expressing recombinant PAR4 are described in Kahn et al.
  • Restoring PAR4 (or its homologue) function in the host cell(s) may be determined by analyzing the host cell(s) for various detectable parameters associated with PAR4 function (i.e., wild type). Such parameters include, but are not limited to, response to thrombin or activating peptides.
  • a secondary screen may comprise testing the agent(s) in human cells if the initial screen has been performed in a host cell other than a human cell.
  • Another screen may comprise testing the agent(s) in a host cell with native PAR4 function if the initial screen has been performed in a host cell without native PAR4 function but being introduced of such function.
  • a cytotoxicity assay would be performed as a further corroboration that an agent which tested positive in a primary screen would be suitable for use in living organisms. Any assay for cytotoxicity would be suitable for this purpose, including, for example the MTT assay (Promega).
  • Kits of the invention also provides kits comprising cathepsin G and/or an mimic of cathepsin G (or compositions comprising cathepsin G and/or an mimic of cathepsin G) in suitable packaging, which further comprise instmctions for administration to an individual in order to effect, or stimulate, PAR4 activation in an individual.
  • the instmctions can be for any of the following: effecting PAR4 activation; stimulation of PAR4-mediated platelet activation; and/or treatment of a condition for which PAR4 activation or stimulation of
  • the mimic of cathepsin G is other than a PAR4-stimulating peptide.
  • the mimic of cathepsin G is AYPGKF.
  • the agent enhances cathepsin G/PAR4 interaction.
  • the kits comprise an agent which interferes with cathepsin
  • kits further comprises instmctions for administering the composition to an individual to effect inhibition of PAR4 activation, inhibition of PAR4-mediated platelet activation, and/or treatment of a condition for which inhibition of PAR4 activation or inhibition of PAR4-mediated platelet activation is indicated.
  • the agent is other than a PAR4 antagonist.
  • cRNA encoding human PARl , PAR3 and PAR4 and mouse PAR2 were microinjected into Xenopus oocytes, respectively. 24 hours later, oocytes were radiolabeled with 45 Ca and responses to 10 nM thrombin or 100 nM cathepsin G stimulation were assessed as calcium mobilization, i.e., 45 Ca release from radiolabeled oocytes, as described in Vu et al. (1991a). Unless indicated otherwise, in all oocyte microinjection experiments, relative expression levels of FLAG epitope-tagged wild type and mutant PAR receptors expressed on the oocytes surface were determined using binding of Ml monoclonal antibodies that were raised against FLAG epitope.
  • K * values were determined by titration of cathepsin G (6 nM) or thrombin (8.5 nM) with various ecotin concentrations. Yang and
  • the activation of PARl or PAR4 induced by cathepsin G was not the result of thrombin contamination in the cathepsin G preparation.
  • Oocytes expressing human PARl or PAR4 were stimulated with 10 nM thrombin or 100 nM cathepsin G in the absence (Control) or presence of the thrombin inhibitors, PPACK (1 ⁇ m), hirudin (10 units/ml), or ecotin (500 nM).
  • Thrombin inhibitors such as himdin or PPACK did not prevent PAR activation by cathepsin G (Figure 2B) but did block activation by thrombin ( Figure 2A).
  • the macromolecular serine protease inhibitor, ecotin blocked cathepsin G- induced calcium responses ( Figure 2B) but had no effect on thrombin ( Figure 2A).
  • the apparent Kj for inhibition of cathepsin G by wild type ecotin was determined to be 15 + 6 pM while the K j for the inhibition of thrombin was 1.1 + 0.2 ⁇ M. This gives ecotin a specific index of 73,000 in favor of blocking cathepsin G and not thrombin.
  • a mutant PARl with a phenylalanine to alanine substitution at position 2 of the tethered ligand (PARl F/A) or a mutant PAR4 with a glycine to proline substitution at position 1 of the tethered ligand (PAR4 G/P) was expressed in Xenopus oocytes as described in Example 1.
  • PARl F/A ablates tethered ligand function in PARl, while PAR4 G/P renders PAR4 uncleavable at the R 47 /G 48 peptide bond.
  • a PARl mutant, PARl F/A in which alanine was substituted for phenylalanine at position 2 of the activation peptide, failed to respond to either thrombin or cathepsin G but did respond to PARl -activating peptide (AP) SFLLRN ( Figure 3).
  • a PAR4 mutant, PAR4 G/P in which a glycine to proline mutation at position 1 of the activation peptide, rendered the receptor uncleavable by thrombin or cathepsin G but still responsive to the PAR4-activating peptide (AP).
  • Cathepsin G activated PARl andPAR4 stably expressed in mammalian cells
  • Lung fibroblasts derived from PARl null mice were cultured in DME containing 10%> bovine calf semm at 37°C in a humidified CO incubator, and were transfected to stably express FLAG epitope-tagged hPARl or hPAR4. Trejo et al. (1996). Calcium mobilization in Fura-2-loaded cells was measured fluorometrically after loading with 4 ⁇ g/ml Fura-2/AM (Molecular Probes) for 30 minutes at 37°C using a Hitachi F2000 fluorometer, and plotted as fluorescence ratio versus time
  • Plasma cells Human platelets were isolated from donor blood collected in 1/5 volume citrate buffer. The first one milliliter drawn was discarded. Blood was centrifuged at 200g for 15 minutes to separate PRP, buffy coat and erythrocytes. Platelets were then washed in buffer (134 mM NaCI, 12 mM NaHCO 3 , 2.9 mM KC1, 0.34 mM Na 2 HPO 4 , 1 mM MgCl2, 10 mM Hepes, 5 mM glucose and 0.3%> BSA) containing postaglandin Ej (1 ⁇ M) and EDTA (10 mM), then resuspended in buffer alone prior to use. Neutrophils were isolated from buffy coat of the same donor blood as platelets.
  • the buffy coat was layered over a 63%) and 72% Percoll solution and centrifuged for 30 minutes at 500g.
  • the polymorphonuclear leukocyte layer was removed, washed with PBS and resuspended in platelet buffer. Aggregometry. Agonist-induced platelet aggregation was measured using a
  • Chrono-Log lumiaggregometer Platelets suspended in buffer described under stirring conditions in the presence of 1 mM CaCl2 were introduced to agonist and change in light transmission measured.
  • Cathepsin G (500 nM) triggered both aggregation and robust increases in cytoplasmic calcium in washed human platelets (Figure 5 and Figure 6).
  • the roles of PARl and PAR4 in this response were first examined by desensitization studies. Platelets preincubated with the PARl -activating peptides SFLLRN (100 ⁇ M) for 30 minutes failed to respond to subsequent challenge with SFLLRN but did respond to cathepsin G ( Figure 5E). By contrast, platelets preincubated with AYPGKF (100 ⁇ M) were refractory to stimulation with cathepsin G but did respond robustly to SFLLRN (Figure 5F). These desensitization studies suggest that signaling via PAR4 but not PARl is required for cathepsin G responses in human platelets.
  • a PAR4-blocking antibody and a PARl -specific antagonist were also used to probe the roles of PARl and PAR4 in platelet responses to cathepsin G. Activation of PARl by thrombin or SFLLRN can be blocked with BMS200261, a peptide-based antagonist that does not block PAR4 activation. Kahn et al. (1999). Similarly, a polyclonal antibody raised to a receptor peptide that spans the thrombin cleavage site of PAR4 blocks cleavage and activation of the receptor by thrombin. Because the antiserum works by blocking cleavage, it does not block PAR4 activation by AYPGKF.
  • Fura-2-loaded platelets (5xl0 7 /ml) and unloaded neutrophils (4xl0 6 /ml) were mixed in the presence of 0.1 mM EGTA and 2.5 ⁇ g/ml cytochalasin B.
  • Calcium mobilization in platelets following stimulation with 100 nM fMLP was measured in the absence ( Figure 7A) or presence (Figure 7B) of 1 mg/ml PAR4-blocking antibody or 1 mg/ml pre-immune IgG ( Figure 7C). Responses shown were plotted as fluorescence ratio versus time (sec).
  • cathepsin G is detectable in solution after neutrophil stimulation and like many other proteases including thrombin, cathepsin G is inhibited by circulating protease inhibitors.
  • a significant proportion of cathepsin G released by neutrophils remains bound to the extracellular membrane where it is catalytically active and relatively resistant to inactivation by protease inhibitors.
  • Owen et al. (1995a) Owen et al. (1995b) J Cell Biol.
  • Cathepsin G-deficient mice showed only a mildly augmented inflammatory response during wound healing but were otherwise without apparent phenotype suggesting that cathepsin G activation of platelet PAR4 is not necessary for survival in an unstressed setting. Brozna (1990) Semin. Thromb. Hemostas. 16:326-332. However, in a stressed, clinical setting, cathepsin G-PAR4 mediated platelet activation could be significant. Clearly, multiple ligand-receptor systems regulate inflammatory and thrombotic responses, and whether deficiencies in other pathways that serve redundant functions might unmask an important role for neutrophil cathepsin G is unknown.
  • activation of platelets by neutrophil cathepsin G may become important only at sites where activated neutrophils and platelets are substantially concentrated, and the effect of cathepsin G deficiency in models that might engender interactions between activated neutrophils and platelets such as the Shwartzman reaction has not been reported.
  • PARs that were originally described as thrombin receptors may also confer responsiveness to proteases other than thrombin.
  • the differential importance of PARl vs. PAR4 for thrombin vs. cathepsin G signaling in human platelets supports the idea that these receptors may serve, at least in part, distinct roles.
  • PAR4 might serve not only to mediate thrombin responsiveness; it might expand the platelet' s repertoire by mediating responses to other proteases.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des méthodes de modulation de l'activation du récepteur PAR4 et/ou de l'activation plaquettaire médiée par la cathepsine G. Par ailleurs, l'invention se rapporte à des méthodes destinées à des agents de criblage pouvant moduler l'activation du récepteur PAR4 et/ou l'activation plaquettaire médiée par la cathepsine G.
PCT/US2001/004987 2000-02-17 2001-02-14 Methodes de modulation de l'activation du recepteur 4 active par des proteases (par4) avec de la cathepsine g Ceased WO2001060401A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001238366A AU2001238366A1 (en) 2000-02-17 2001-02-14 Methods of modulating protease-activated receptor-4 (par4) activation via cathepsin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50643100A 2000-02-17 2000-02-17
US09/506,431 2000-02-17

Publications (1)

Publication Number Publication Date
WO2001060401A1 true WO2001060401A1 (fr) 2001-08-23

Family

ID=24014563

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/004987 Ceased WO2001060401A1 (fr) 2000-02-17 2001-02-14 Methodes de modulation de l'activation du recepteur 4 active par des proteases (par4) avec de la cathepsine g

Country Status (2)

Country Link
AU (1) AU2001238366A1 (fr)
WO (1) WO2001060401A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004080372A3 (fr) * 2003-03-11 2005-05-12 Bayer Healthcare Ag Diagnostic et traitement de maladies associees au recepteur 4 active par la proteinase et couple aux proteines g (par 4)
US20110104146A1 (en) * 2007-06-19 2011-05-05 The John Hopkins University Antithrombotic agents and methods of use thereof
US12077607B2 (en) 2021-09-23 2024-09-03 University Of Utah Research Foundation Functional and therapeutic effects of PAR4 cleavage by cathepsin G

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043809A2 (fr) * 1998-02-27 1999-09-02 The Regents Of The University Of California Recepteur 4 active par la protease et ses utilisations
WO2001007072A1 (fr) * 1999-07-23 2001-02-01 The Regents Of The University Of California Modulation de l'activation plaquettaire

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043809A2 (fr) * 1998-02-27 1999-09-02 The Regents Of The University Of California Recepteur 4 active par la protease et ses utilisations
WO2001007072A1 (fr) * 1999-07-23 2001-02-01 The Regents Of The University Of California Modulation de l'activation plaquettaire

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FARUQI TATJANA R ET AL: "Structure-function analysis of protease-activated receptor 4 tethered ligand peptides: Determinants of specificity and utility in assays of receptor function", JOURNAL OF BIOLOGICAL CHEMISTRY,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD,US, vol. 275, no. 26, 30 June 2000 (2000-06-30), pages 19728 - 19734, XP002162838, ISSN: 0021-9258 *
KAHN ET AL: "PROTEASE-ACTIVATED RECEPTORS 1 AND 4 MEDIATE ACTIVATION OF HUMAN PLATELETS BY THROMBIN", JOURNAL OF CLINICAL INVESTIGATION,NEW YORK, NY,US, vol. 103, no. 6, 1999, pages 879 - 887, XP002162839, ISSN: 0021-9738 *
KAHN M L ET AL: "A dual thrombin receptor system for platelet activation", NATURE,MACMILLAN JOURNALS LTD. LONDON,GB, vol. 394, no. 6694, 13 August 1998 (1998-08-13), pages 690 - 694, XP002112287, ISSN: 0028-0836 *
KINLOUGH-RATHBONE ET AL: "Effects of Cathepsin G Pretreatment of Platelets on their Subsequent Responses to Aggregating Agents", THROMBOSIS RESEARCH, vol. 95, 1999, pages 315-323, XP000999936 *
SAMBRANO ET AL: "Cathepsin G Activates Protease-activated Receptor-4 in Human Platelets", J BIOL CHEM, vol. 275, no. 10, 10 March 2000 (2000-03-10), pages 6819 - 6823, XP002168580 *
XU ET AL: "Cloning and characterisation of human protease-activated receptor 4", PNAS, vol. 95, June 1999 (1999-06-01), pages 6642 - 6646, XP002112286 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004080372A3 (fr) * 2003-03-11 2005-05-12 Bayer Healthcare Ag Diagnostic et traitement de maladies associees au recepteur 4 active par la proteinase et couple aux proteines g (par 4)
US20110104146A1 (en) * 2007-06-19 2011-05-05 The John Hopkins University Antithrombotic agents and methods of use thereof
US9585899B2 (en) * 2007-06-19 2017-03-07 The Johns Hopkins University Method of inhibiting platelet aggregation and clot formation
US12077607B2 (en) 2021-09-23 2024-09-03 University Of Utah Research Foundation Functional and therapeutic effects of PAR4 cleavage by cathepsin G

Also Published As

Publication number Publication date
AU2001238366A1 (en) 2001-08-27

Similar Documents

Publication Publication Date Title
Esmon Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface
Kato et al. Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig
Sambrano et al. Cathepsin G activates protease-activated receptor-4 in human platelets
Quinton et al. Plasmin-mediated activation of platelets occurs by cleavage of protease-activated receptor 4
Lourbakos et al. Cleavage and activation of proteinase-activated receptor-2 on human neutrophils by gingipain-R from Porphyromonas gingivalis
Colman et al. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes
Mackie et al. Protease‐activated receptors: a means of converting extracellular proteolysis into intracellular signals
Parr et al. Association of mouse fibrinogen-like protein with murine hepatitis virus-induced prothrombinase activity
CA2408883A1 (fr) Procedes pour diagnostiquer et traiter des troubles hemostatiques par modulation de l'activite de la p-selectine
Pei CA-MMP: a matrix metalloproteinase with a novel cysteine array, but without the classic cysteine switch
US5892014A (en) DNA encoding a protease-activated receptor 3
Gui et al. Abnormal hemostasis in a knock‐in mouse carrying a variant of factor IX with impaired binding to collagen type IV
McLean et al. FXa-induced responses in vascular wall cells are PAR-mediated and inhibited by ZK-807834
Xu et al. Endogenous activated protein C signaling is critical to protection of mice from lipopolysaccaride-induced septic shock
EP1056854A2 (fr) Recepteur 4 active par la protease et ses utilisations
Stief Coagulation activation by lipopolysaccharides
Wang et al. Primary structure and antiplatelet mechanism of a snake venom metalloproteinase, acurhagin, from Agkistrodon acutus venom
Espana et al. The multifunctional protein C system
Hourcade et al. Decay acceleration of the complement alternative pathway C3 convertase
Petersen et al. Tissue factor-dependent factor VIIa signaling
NO314848B1 (no) Protein for inhibering av kollagenfremkalt blodplateaggregering, DNA som koder for proteinet, vektor som omfatter et slikt DNA, vertscelletransformert medvektoren, fremgangsmåter for fremstilling og rensing avproteinet, farmasöytiskpreparat
CA2378473A1 (fr) Modulation de l'activation plaquettaire
WO2001060401A1 (fr) Methodes de modulation de l'activation du recepteur 4 active par des proteases (par4) avec de la cathepsine g
Wang Purification and functional characterization of AAV1, a novel P-III metalloproteinase, from Formosan Agkistrodon acutus venom
WO2001094411A1 (fr) Peptides modulant des recepteurs actives par des recepteurs de protease et methodes d'utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP